Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Feb 28;15(8):966-72.
doi: 10.3748/wjg.15.966.

Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial

Affiliations
Clinical Trial

Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial

Gadi Lalazar et al. World J Gastroenterol. .

Abstract

Aim: To assess the role of the (13)C-methacetin breath test (MBT) in patients with acute liver disease.

Methods: Fifteen patients with severe acute liver disease from diverse etiologies were followed-up with (13)C-MBT during the acute phase of their illnesses (range 3-116 d after treatment). Patients fasted for 8 h and ingested 75 mg of methacetin prior to the MBT. We compared results from standard clinical assessment, serum liver enzymes, synthetic function, and breath test scores.

Results: Thirteen patients recovered and two patients died. In patients that recovered, MBT parameters improved in parallel with improvements in lab results. Evidence of consistent improvement began on day 3 for MBT parameters and between days 7 and 9 for blood tests. Later convergence to normality occurred at an average of 9 d for MBT parameters and from 13 to 28 d for blood tests. In both patients that died, MBT parameters remained low despite fluctuating laboratory values.

Conclusion: The (13)C-MBT provides a rapid, non-invasive assessment of liver function in acute severe liver disease of diverse etiologies. The results of this pilot clinical trial suggest that the MBT may offer greater sensitivity than standard clinical tests for managing patients with severe acute liver disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
This is an illustration of typical breath test and blood test results plotted over the clinical time course. The wide green line indicates the range of normal values. As the patient recovered, test results converged toward normality.
Figure 2
Figure 2
The clinical course of a patient with fulminant auto-immune hepatitis. A: Upon admission, aminotransferase levels were well above 10 × ULN, INR was increased, and breath test values were low. The patient received treatment with steroids and recovered rapidly. The breath test values normalized within 3 d, but blood tests began normalizing 2 d later; B: Despite therapy with steroids, this patient failed to improve, developed gram negative sepsis, and died. Note that despite stable blood tests, there was a lack of improvement in breath test values. The low breath test values may have been a negative prognostic factor in this patient and may have provided a rationale for early transplantation.

Similar articles

Cited by

References

    1. Elias E. Liver failure and liver disease. Hepatology. 2006;43:S239–S242. - PubMed
    1. Davis CL, Gonwa TA, Wilkinson AH. Identification of patients best suited for combined liver-kidney transplantation: part II. Liver Transpl. 2002;8:193–211. - PubMed
    1. Han MK, Hyzy R. Advances in critical care management of hepatic failure and insufficiency. Crit Care Med. 2006;34:S225–S231. - PubMed
    1. Blei AT. Selection for acute liver failure: have we got it right? Liver Transpl. 2005;11:S30–S34. - PubMed
    1. Kamath PS, Kim WR. The model for end-stage liver disease (MELD) Hepatology. 2007;45:797–805. - PubMed

Publication types

MeSH terms